GlassScriptPhysician profile
Ghassan Daher
NPI 1407378078
$23,460.73
in general payments reported to CMS, 2019-2025
26 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $319 · 2023: $709 · 2024: $709 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Food and Beverage: $3,692 · Travel and Lodging: $1,579 · Education: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $17,500.00 |
| Food and Beverage | $3,691.87 |
| Travel and Lodging | $1,578.69 |
| Education | $371.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,180.22 | 2023-2025 | Xience V, Optis, Ultreon |
| Medtronic, INC. | $4,231.91 | 2022-2025 | Onyx Frontier |
| Boston Scientific Corporation | $511.41 | 2025 | General - Therapies, Avvigo Guidance System, General - Vascular Access |
| Abiomed | $324.54 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.58 | 2022-2024 | Lifevest |
| Pfizer INC. | $243.35 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $232.19 | 2025 | |
| Janssen Pharmaceuticals, INC | $195.83 | 2022-2024 | Xarelto |
| Inari Medical, INC. | $166.95 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $164.06 | 2025 | |
| Inquis Medical, INC. | $158.51 | 2025 | Aventus |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Actelion Pharmaceuticals US, INC. | $113.52 | 2024 | Opsumit, Uptravi |
| Atricure, INC. | $81.03 | 2023-2025 | Synergy Ablation System |
| Gilead Sciences, INC. | $79.57 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $60.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $54.76 | 2024-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $53.95 | 2024-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $35.19 | 2022-2024 | Livtencity |
| Chiesi USA, INC. | $23.02 | 2024 | Kengreal, Cleviprex |
| Novo Nordisk INC | $20.80 | 2024 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $20.34 | 2024 | |
| Zoll Circulation INC | $20.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.06 | 2024 | Onpattro |
| Genzyme Corporation | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.